The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
Microbial systems are a black box. We created Microbial INtelligence Explorer to “MINE” their secrets• Microbiotica Raises $48 Million Series C to Advance Pipeline into Phase 2 Clinical Development• Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment• Claude Discovers Novel Enzyme System with CRISPR-like Repeats• New Clinical Study Aims to Find Out if FMT capsules could help better manage anorexia• MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination•

Nick Gallo

Microbial systems are a black box. We created Microbial INtelligence Explorer to “MINE” their secrets
Biotics and Supplements

Microbial systems are a black box. We created Microbial INtelligence Explorer to “MINE” their secrets

OCT 22, 2026
Microbiotica Raises $48 Million Series C to Advance Pipeline into Phase 2 Clinical Development
Clinical & Manufacturing

Microbiotica Raises $48 Million Series C to Advance Pipeline into Phase 2 Clinical Development

OCT 16, 2026
Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment
Editor's Choice

Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment

SEP 28, 2026
Claude Discovers Novel Enzyme System with CRISPR-like Repeats
GMO & Synbio

Claude Discovers Novel Enzyme System with CRISPR-like Repeats

SEP 25, 2026
New Clinical Study Aims to Find Out if FMT capsules could help better manage anorexia
Clinical & Manufacturing

New Clinical Study Aims to Find Out if FMT capsules could help better manage anorexia

SEP 24, 2026
MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination
Clinical & Manufacturing

MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination

SEP 18, 2026
Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
Infectious Disease & AMR

Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02

SEP 15, 2026
GutAlive®: Microbiota Collection and Transport in Anaerobic Conditions
Clinical & Manufacturing

GutAlive®: Microbiota Collection and Transport in Anaerobic Conditions

SEP 11, 2026
From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics
Clinical & Manufacturing

From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics

SEP 4, 2026
Stanford’s AI Designed Bacteriophages: Ushering in the Next Phase in IP Strategy for Phage Companies?
Editor's Choice

Stanford’s AI Designed Bacteriophages: Ushering in the Next Phase in IP Strategy for Phage Companies?

AUG 10, 2026
Beyond the small intestine: ileo colonic delivery as the next frontier for oral therapeutics
Gastrointestinal

Beyond the small intestine: ileo colonic delivery as the next frontier for oral therapeutics

JUN 10, 2026